General Questions About Retatrutide
What is retatrutide, who makes it, how is it different from Ozempic and Mounjaro, and when might it be available?
What is retatrutide?
Retatrutide (LY3437943) is an investigational medication developed by Eli Lilly and Company. It is a single peptide molecule that simultaneously activates three metabolic hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple receptor agonism is a novel approach designed to address obesity and type 2 diabetes through complementary metabolic pathways.
Is retatrutide FDA-approved?
No. As of May 2026, retatrutide is an investigational compound in late-stage Phase 3 clinical development. It has not been approved by the FDA or any other regulatory authority worldwide. Three pivotal Phase 3 trials have reported positive topline results — TRIUMPH-4 (Dec 2025), TRANSCEND-T2D-1 (March 19, 2026), and TRIUMPH-1 (May 21, 2026) — but Eli Lilly has not yet filed a New Drug Application. The drug is not available for prescription or commercial purchase. Any legitimate use is limited to authorized clinical trials.
Who is developing retatrutide?
Retatrutide is being developed by Eli Lilly and Company, a major pharmaceutical company based in Indianapolis, Indiana. Lilly also developed tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity), which is a related dual GIP/GLP-1 receptor agonist.
What does LY3437943 mean?
LY3437943 is retatrutide's development code assigned by Eli Lilly. The 'LY' prefix identifies it as a Lilly compound, and the numerical designation is its internal identifier. 'Retatrutide' is the drug's International Nonproprietary Name (INN), which is the standardized name for scientific and medical communication.
What conditions is retatrutide being studied for?
Retatrutide is primarily being studied for the treatment of obesity and weight management in the Phase 3 TRIUMPH program (4 trials: TRIUMPH-1 through TRIUMPH-4, plus TRIUMPH-Outcomes for cardiovascular events). The separate TRANSCEND program (TRANSCEND-T2D-1, T2D-2, T2D-3, CKD) evaluates retatrutide for type 2 diabetes. It is also being evaluated for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) in dedicated trials: the SYNERGY trial and the MACELD Phase 3 trial, which launched in Q4 2025. The Phase 2 data showed significant liver fat reduction with 86% of participants at the 12 mg dose achieving normal liver fat levels, supporting the dedicated liver disease program.
How is retatrutide different from semaglutide or tirzepatide?
Semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor. Tirzepatide (Mounjaro/Zepbound) targets both GIP and GLP-1 receptors. Retatrutide targets all three: GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure and promote liver fat reduction, which are effects not available from single or dual agonists.
Does retatrutide have a brand name?
No. Retatrutide does not have a brand name because it has not received marketing authorization from any regulatory agency. Brand names are typically assigned during the regulatory approval process. The drug is referred to by its INN (retatrutide) or development code (LY3437943) in scientific literature.
When might retatrutide be available?
Eli Lilly maintained NDA filing guidance of late 2026 to Q1 2027 at its Q1 2026 earnings call (April 30, 2026), after positive readouts from TRIUMPH-4 (December 2025), TRANSCEND-T2D-1 (March 19, 2026), and TRIUMPH-1 (May 21, 2026). Based on this timeline, FDA approval could come as early as mid-to-late 2027 with Priority Review, or late 2027 to early 2028 under standard review. These are estimates and depend on the remaining TRIUMPH-2 and TRIUMPH-3 readouts (expected H2 2026) and regulatory decisions.